Cargando…

Taurolidine-citrate lock solution (TauroLock) significantly reduces CVAD-associated grampositive infections in pediatric cancer patients

BACKGROUND: Taurolidin/Citrate (TauroLock™), a lock solution with broad spectrum antimicrobial activity, may prevent bloodstream infection (BSI) due to coagulase-negative staphylococci (CoNS or 'MRSE' in case of methicillin-resistant isolates) in pediatric cancer patients with a long term...

Descripción completa

Detalles Bibliográficos
Autores principales: Simon, Arne, Ammann, Roland A, Wiszniewsky, Gertrud, Bode, Udo, Fleischhack, Gudrun, Besuden, Mette M
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2008
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2515312/
https://www.ncbi.nlm.nih.gov/pubmed/18664278
http://dx.doi.org/10.1186/1471-2334-8-102
_version_ 1782158412289671168
author Simon, Arne
Ammann, Roland A
Wiszniewsky, Gertrud
Bode, Udo
Fleischhack, Gudrun
Besuden, Mette M
author_facet Simon, Arne
Ammann, Roland A
Wiszniewsky, Gertrud
Bode, Udo
Fleischhack, Gudrun
Besuden, Mette M
author_sort Simon, Arne
collection PubMed
description BACKGROUND: Taurolidin/Citrate (TauroLock™), a lock solution with broad spectrum antimicrobial activity, may prevent bloodstream infection (BSI) due to coagulase-negative staphylococci (CoNS or 'MRSE' in case of methicillin-resistant isolates) in pediatric cancer patients with a long term central venous access device (CVAD, Port- or/Broviac-/Hickman-catheter type). METHODS: In a single center prospective 48-months cohort study we compared all patients receiving anticancer chemotherapy from April 2003 to March 2005 (group 1, heparin lock with 200 IU/ml sterile normal saline 0.9%; Canusal(® )Wockhardt UK Ltd, Wrexham, Wales) and all patients from April 2005 to March 2007 (group 2; taurolidine 1.35%/Sodium Citrate 4%; TauroLock™, Tauropharm, Waldbüttelbrunn, Germany). RESULTS: In group 1 (heparin), 90 patients had 98 CVAD in use during the surveillance period. 14 of 30 (47%) BSI were 'primary Gram positive BSI due to CoNS (n = 4) or MRSE (n = 10)' [incidence density (ID); 2.30 per 1000 inpatient CVAD-utilization days]. In group 2 (TauroLock™), 89 patients had 95 CVAD in use during the surveillance period. 3 of 25 (12%) BSI were caused by CoNS. (ID, 0.45). The difference in the ID between the two groups was statistically significant (P = 0.004). CONCLUSION: The use of Taurolidin/Citrate (TauroLock™) significantly reduced the number and incidence density of primary catheter-associated BSI due to CoNS and MRSE in pediatric cancer patients.
format Text
id pubmed-2515312
institution National Center for Biotechnology Information
language English
publishDate 2008
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-25153122008-08-13 Taurolidine-citrate lock solution (TauroLock) significantly reduces CVAD-associated grampositive infections in pediatric cancer patients Simon, Arne Ammann, Roland A Wiszniewsky, Gertrud Bode, Udo Fleischhack, Gudrun Besuden, Mette M BMC Infect Dis Research Article BACKGROUND: Taurolidin/Citrate (TauroLock™), a lock solution with broad spectrum antimicrobial activity, may prevent bloodstream infection (BSI) due to coagulase-negative staphylococci (CoNS or 'MRSE' in case of methicillin-resistant isolates) in pediatric cancer patients with a long term central venous access device (CVAD, Port- or/Broviac-/Hickman-catheter type). METHODS: In a single center prospective 48-months cohort study we compared all patients receiving anticancer chemotherapy from April 2003 to March 2005 (group 1, heparin lock with 200 IU/ml sterile normal saline 0.9%; Canusal(® )Wockhardt UK Ltd, Wrexham, Wales) and all patients from April 2005 to March 2007 (group 2; taurolidine 1.35%/Sodium Citrate 4%; TauroLock™, Tauropharm, Waldbüttelbrunn, Germany). RESULTS: In group 1 (heparin), 90 patients had 98 CVAD in use during the surveillance period. 14 of 30 (47%) BSI were 'primary Gram positive BSI due to CoNS (n = 4) or MRSE (n = 10)' [incidence density (ID); 2.30 per 1000 inpatient CVAD-utilization days]. In group 2 (TauroLock™), 89 patients had 95 CVAD in use during the surveillance period. 3 of 25 (12%) BSI were caused by CoNS. (ID, 0.45). The difference in the ID between the two groups was statistically significant (P = 0.004). CONCLUSION: The use of Taurolidin/Citrate (TauroLock™) significantly reduced the number and incidence density of primary catheter-associated BSI due to CoNS and MRSE in pediatric cancer patients. BioMed Central 2008-07-29 /pmc/articles/PMC2515312/ /pubmed/18664278 http://dx.doi.org/10.1186/1471-2334-8-102 Text en Copyright © 2008 Simon et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Simon, Arne
Ammann, Roland A
Wiszniewsky, Gertrud
Bode, Udo
Fleischhack, Gudrun
Besuden, Mette M
Taurolidine-citrate lock solution (TauroLock) significantly reduces CVAD-associated grampositive infections in pediatric cancer patients
title Taurolidine-citrate lock solution (TauroLock) significantly reduces CVAD-associated grampositive infections in pediatric cancer patients
title_full Taurolidine-citrate lock solution (TauroLock) significantly reduces CVAD-associated grampositive infections in pediatric cancer patients
title_fullStr Taurolidine-citrate lock solution (TauroLock) significantly reduces CVAD-associated grampositive infections in pediatric cancer patients
title_full_unstemmed Taurolidine-citrate lock solution (TauroLock) significantly reduces CVAD-associated grampositive infections in pediatric cancer patients
title_short Taurolidine-citrate lock solution (TauroLock) significantly reduces CVAD-associated grampositive infections in pediatric cancer patients
title_sort taurolidine-citrate lock solution (taurolock) significantly reduces cvad-associated grampositive infections in pediatric cancer patients
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2515312/
https://www.ncbi.nlm.nih.gov/pubmed/18664278
http://dx.doi.org/10.1186/1471-2334-8-102
work_keys_str_mv AT simonarne taurolidinecitratelocksolutiontaurolocksignificantlyreducescvadassociatedgrampositiveinfectionsinpediatriccancerpatients
AT ammannrolanda taurolidinecitratelocksolutiontaurolocksignificantlyreducescvadassociatedgrampositiveinfectionsinpediatriccancerpatients
AT wiszniewskygertrud taurolidinecitratelocksolutiontaurolocksignificantlyreducescvadassociatedgrampositiveinfectionsinpediatriccancerpatients
AT bodeudo taurolidinecitratelocksolutiontaurolocksignificantlyreducescvadassociatedgrampositiveinfectionsinpediatriccancerpatients
AT fleischhackgudrun taurolidinecitratelocksolutiontaurolocksignificantlyreducescvadassociatedgrampositiveinfectionsinpediatriccancerpatients
AT besudenmettem taurolidinecitratelocksolutiontaurolocksignificantlyreducescvadassociatedgrampositiveinfectionsinpediatriccancerpatients